Literature DB >> 15322565

Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients.

Anne-Sophie Arnold1, Mor Gueye, Séverine Guettier-Sigrist, Isabelle Courdier-Fruh, Gilliane Coupin, Philippe Poindron, Jean-Pierre Gies.   

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motoneurons and skeletal muscle atrophy. In its most severe form, it leads to death before the age of 2 years. While primary degeneration of motor neurons is well established in this disease, and this results in neurogenic atrophy of skeletal muscle, we have previously reported evidence for a primary muscle defect. In this study, we used primary cultures of embryonic human skeletal muscle cells from patients with SMA and from controls to examine the effects of muscle fiber differentiation in the absence of a nerve component. Cultured SMA skeletal muscle cells are unable to fuse correctly to form multinuclear myotubes, the precursors of the myofibers. We also show that agrin-induced aggregates of nicotinic acetylcholine receptors, one of the earliest steps of neuromuscular junction formation, cannot be visualized by confocal microscopy on cells from SMA patients. In binding experiments, we demonstrate that this lack of clustering is due to defective expression of the nicotinic acetylcholine receptors in the myotubes of SMA patients whereas the affinity of alpha-bungarotoxin for its receptor remains unchanged regardless of muscle cell type (SMA or control). These observations suggest that muscle cells from SMA patients have intrinsic abnormalities that may affect proper formation of the neuromuscular junction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322565     DOI: 10.1038/labinvest.3700163

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  38 in total

1.  Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics.

Authors:  Katherine V Bricceno; Tara Martinez; Evgenia Leikina; Stephanie Duguez; Terence A Partridge; Leonid V Chernomordik; Kenneth H Fischbeck; Charlotte J Sumner; Barrington G Burnett
Journal:  Hum Mol Genet       Date:  2014-04-23       Impact factor: 6.150

2.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

3.  Compensatory axon sprouting for very slow axonal die-back in a transgenic model of spinal muscular atrophy type III.

Authors:  Esther Udina; Charles T Putman; Luke R Harris; Neil Tyreman; Victoria E Cook; Tessa Gordon
Journal:  J Physiol       Date:  2017-01-25       Impact factor: 5.182

4.  Reorganization of the nuclear compartments involved in transcription and RNA processing in myonuclei of type I spinal muscular atrophy.

Authors:  María S Castillo-Iglesias; María T Berciano; J Oriol Narcis; J Fernando Val-Bernal; José C Rodriguez-Rey; Olga Tapia; Miguel Lafarga
Journal:  Histochem Cell Biol       Date:  2019-06-11       Impact factor: 4.304

5.  Genetic inhibition of JNK3 ameliorates spinal muscular atrophy.

Authors:  Naresh K Genabai; Saif Ahmad; Zhanying Zhang; Xiaoting Jiang; Cynthia A Gabaldon; Laxman Gangwani
Journal:  Hum Mol Genet       Date:  2015-09-30       Impact factor: 6.150

Review 6.  Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications?

Authors:  Chiara Simone; Agnese Ramirez; Monica Bucchia; Paola Rinchetti; Hardy Rideout; Dimitra Papadimitriou; Diane B Re; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2015-12-18       Impact factor: 9.261

7.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.

Authors:  Shingo Kariya; Teresa Obis; Caterina Garone; Turgay Akay; Fusako Sera; Shinichi Iwata; Shunichi Homma; Umrao R Monani
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 8.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

9.  SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain.

Authors:  Michael P Walker; T K Rajendra; Luciano Saieva; Jennifer L Fuentes; Livio Pellizzoni; A Gregory Matera
Journal:  Hum Mol Genet       Date:  2008-08-08       Impact factor: 6.150

10.  Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.

Authors:  Shingo Kariya; Gyu-Hwan Park; Yuka Maeno-Hikichi; Olga Leykekhman; Cathleen Lutz; Marc S Arkovitz; Lynn T Landmesser; Umrao R Monani
Journal:  Hum Mol Genet       Date:  2008-05-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.